查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193231

镰状细胞治疗市场:按药物类型、按类型、给药途径：全球机会分析和行业预测，2021-2031年

Sickle Cell Disease Treatment Market By Drug Type (Hydroxyurea, Oxybryta, Adakveo, Others), By Type (Sickle Cell Anemia, HbSC, Others), By Route of Administration (Oral, Parenteral): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 292 Pages | 商品交期: 2-3个工作天内

价格

2021 年全球镰状细胞治疗市场价值 10.7888 亿美元，2022 年至 2031 年的复合年增长率为 4.1%，预计到 2031 年将达到 16.1878 亿美元。

圆形、健康的红细胞穿过细小的血液通道，将氧气输送到身体的各个部位。 在镰状细胞病中，血红蛋白的缺陷会导致红细胞变成称为镰状细胞的 C 形细胞，这种细胞又硬又粘。 镰状细胞病的症状包括贫血、疼痛和手脚肿胀。

全球镰状细胞治疗市场的增长是由镰状细胞病的日益流行、镰状细胞药物的可用性以及政府发展更好的医疗基础设施的努力推动的。是主要因素。 例如，根据美国疾病控制和预防中心的数据，非洲每 360 名新生儿中就有 1 名患有镰状细胞病，而患有镰状细胞病的新生儿中，每 13 名婴儿中就有 1 名具有某种特征。

但是，与镰状细胞病相关的高昂治疗费用以及与镰状细胞病相关的副作用可能会阻碍市场增长。 相反，扩大研发渠道、正在进行的药物批准以及未开发新市场的强劲增长潜力预计将在预测期内为市场增长提供大量机会。

全球镰状细胞病治疗市场根据药物类型、类型、给药途径和地区进行细分，以提供深入的市场评估。 按药物类型分为羟基尿、oxbrita、adacveo 等。 其他还包括 Endari、止痛药等。

目次

第 1 章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 定位顶级玩家
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 分析 COVID-19 对市场的影响
  • 专利情况

第 4 章镰状细胞治疗市场：按药物类型分类

  • 概览
    • 市场规模和预测
  • Hydroxyurea
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
    • 羟基尿镰状细胞病治疗市场：按分销渠道
      • 医院和药房市场规模和预测：按地区
      • 药店和配药店的市场规模和预测：按地区
      • 在线提供商市场规模和预测：按地区
  • Oxybryta
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • Adakveo
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章镰状细胞治疗市场：按类型

  • 概览
    • 市场规模和预测
  • 镰状细胞性贫血
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • HbSC
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章镰状细胞治疗市场：按给药途径

  • 概览
    • 市场规模和预测
  • 口服
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 非口服
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 7 章镰状细胞治疗市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按药物分类
      • 北美羟基尿镰状细胞治疗市场：按分销渠道
    • 北美市场规模和预测：按类型分类
    • 北美市场规模和预测：按给药途径
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 加拿大
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 墨西哥
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按药物分类
      • 欧洲羟基尿镰状细胞治疗市场：按分销渠道
    • 欧洲市场规模和预测：按类型
    • 欧洲市场规模和预测：按给药途径
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 法国
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 英国
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 意大利
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 西班牙
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 其他欧洲
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
  • 亚太地区
    • 主要趋势和机会
    • 亚太地区市场规模和按药物类型预测
      • 亚太地区羟基尿镰状细胞治疗市场：按分销渠道
    • 亚太市场规模和预测：按类型分类
    • 亚太地区市场规模和按给药途径预测
    • 亚太市场规模和预测：按国家/地区分类
      • 日本
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 中国
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 印度
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 澳大利亚
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 韩国
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 其他亚太地区
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
  • 拉丁美洲/中东/非洲
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按药物分类
      • LAMEA 羟基尿镰状细胞治疗市场：按分销渠道
    • LAMEA 市场规模和预测：按类型
    • LAMEA 市场规模和按给药途径预测
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 沙特阿拉伯
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 南非
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测
      • 拉丁美洲其他地区/中东/非洲
      • 市场规模和预测：按药物分类
      • 市场规模和按类型预测
      • 市场规模和按给药途径预测

第 8 章企业情势

  • 介绍
  • 关键成功策略
  • 排名前 10 位的玩家产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第 9 章公司简介

  • Agios Pharmaceuticals
  • Bristol-Myers Squibb
  • CRISPR Therapeutics
  • editas Medicine
  • Emmaus Life Sciences, Inc.
  • Global Blood Therapeutics, Inc.
  • Medunic USA Inc.
  • Novartis AG
  • Novo Nordisk
  • Vifor Pharma
Product Code: A31450

The global sickle cell disease treatment market was valued at $ 1,078.88 million in 2021 and is projected to reach $1,618.78million by 2031, registering a CAGR of 4.1% from 2022 to 2031. 

The round and healthy red blood cells move through small blood channels to deliver oxygen to every part of the body. In sickle cell disease patients, the hemoglobin is abnormal, which causes the red blood cells get transformed into C-shaped cells called as a sickles and become hard and sticky. The symptoms of sickle cell disease includes, anemia, episodes of pain, and swelling of hands and feet. 

The growth of the global sickle cell disease treatment market is majorly driven by increase in prevalence of sickle cell disease, availability of sickle cell disease medications, and initiatives taken by government to develop better healthcare infrastructure. For instance, according to Centers for Disease Control and Prevention, sickle cell disease affects 1 of every 360 African new born and 1 in 13 babies born carries the sickle cell trait. 

However, high cost of treatment associated with sickle cell disease treatment and side effects associated with sickle cell disease may hinder the market growth. Conversely, expansion of R&D pipeline, ongoing medicine approvals, and strong growth potential in unexplored new markets are expected to provide numerous opportunities for the market growth during the forecast period.

The global sickle cell disease treatment market is segmented on the basis of drug type, type, route of administration, and region to provide a detailed assessment of the market. By drug type, it is segmented into hydroxyurea, oxbryta, adakveo, and others. The others segment further includes, endari, pain-relieving medication, and others. 

In addition, on the basis of type is segmented into sickle cell anemia or HbSS, HbSC, and others. The others segment further includes, HbS beta thalassemia, HbSD, HbSE, and HbSO. By route of administration, it is segmented into oral and parenteral. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The key market players profiled in the report include Agios Pharmaceuticals, Bristol Myers Squibb Company, CRISPR Therapeutics, Editas Medicine, Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., Medunic USA, Inc., Novartis AG, Novo Nordisk, and Vifor Pharma.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sickle cell disease treatment market analysis from 2021 to 2031 to identify the prevailing sickle cell disease treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the sickle cell disease treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global sickle cell disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Hydroxyurea
    • Distribution Channel
    • Hospitals Pharmacies
    • Drug Stores and Retail Pharmacies
    • Online Providers
  • Oxybryta
  • Adakveo
  • Others

By Type

  • Sickle Cell Anemia
  • HbSC
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Agios Pharmaceuticals
    • Bristol-Myers Squibb
    • CRISPR Therapeutics
    • editas Medicine
    • Emmaus Life Sciences, Inc.
    • Global Blood Therapeutics, Inc.
    • Medunic USA Inc.
    • Novartis AG
    • Novo Nordisk
    • Vifor Pharma

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Hydroxyurea
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
      • 4.2.4.1 Hospitals Pharmacies Market size and forecast, by region
      • 4.2.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
      • 4.2.4.3 Online Providers Market size and forecast, by region
  • 4.3 Oxybryta
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Adakveo
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Others
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Sickle Cell Anemia
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 HbSC
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Oral
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Parenteral
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country

CHAPTER 7: SICKLE CELL DISEASE TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Type
      • 7.2.2.1 North America Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
    • 7.2.3 North America Market size and forecast, by Type
    • 7.2.4 North America Market size and forecast, by Route of Administration
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Type
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Route of Administration
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Type
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Route of Administration
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Type
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Route of Administration
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Type
      • 7.3.2.1 Europe Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
    • 7.3.3 Europe Market size and forecast, by Type
    • 7.3.4 Europe Market size and forecast, by Route of Administration
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Type
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Route of Administration
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Type
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Route of Administration
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Type
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Route of Administration
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Type
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Route of Administration
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Type
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Route of Administration
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Type
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Route of Administration
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
      • 7.4.2.1 Asia-Pacific Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
    • 7.4.3 Asia-Pacific Market size and forecast, by Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug Type
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Route of Administration
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug Type
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Route of Administration
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Drug Type
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Route of Administration
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Drug Type
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Route of Administration
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Type
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Route of Administration
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Type
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Route of Administration
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Type
      • 7.5.2.1 LAMEA Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
    • 7.5.3 LAMEA Market size and forecast, by Type
    • 7.5.4 LAMEA Market size and forecast, by Route of Administration
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Type
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Route of Administration
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Type
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Route of Administration
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Type
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Route of Administration
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Type
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Route of Administration

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Agios Pharmaceuticals
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Bristol-Myers Squibb
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 CRISPR Therapeutics
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 editas Medicine
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Emmaus Life Sciences, Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Global Blood Therapeutics, Inc.
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Medunic USA Inc.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Novartis AG
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Novo Nordisk
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Vifor Pharma
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 2. SICKLE CELL DISEASE TREATMENT MARKET, FOR HYDROXYUREA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. SICKLE CELL DISEASE TREATMENT MARKET FOR HYDROXYUREA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 5. SICKLE CELL DISEASE TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. SICKLE CELL DISEASE TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. SICKLE CELL DISEASE TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. SICKLE CELL DISEASE TREATMENT MARKET, FOR OXYBRYTA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. SICKLE CELL DISEASE TREATMENT MARKET FOR OXYBRYTA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. SICKLE CELL DISEASE TREATMENT MARKET, FOR ADAKVEO, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. SICKLE CELL DISEASE TREATMENT MARKET FOR ADAKVEO, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 15. SICKLE CELL DISEASE TREATMENT MARKET, FOR SICKLE CELL ANEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. SICKLE CELL DISEASE TREATMENT MARKET FOR SICKLE CELL ANEMIA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. SICKLE CELL DISEASE TREATMENT MARKET, FOR HBSC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. SICKLE CELL DISEASE TREATMENT MARKET FOR HBSC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 22. SICKLE CELL DISEASE TREATMENT MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. SICKLE CELL DISEASE TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. SICKLE CELL DISEASE TREATMENT MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. SICKLE CELL DISEASE TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. SICKLE CELL DISEASE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 33. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 35. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 36. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 50. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 52. UK SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 53. UK SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. UK SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 55. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 56. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 72. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 73. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 74. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 75. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 76. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 91. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 94. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 96. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 97. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 102. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 103. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 104.AGIOS PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 105.AGIOS PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 106.AGIOS PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 107.AGIOS PHARMACEUTICALS: NET SALES,
  • TABLE 108.AGIOS PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 109.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 110.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 111.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 112.BRISTOL-MYERS SQUIBB: NET SALES,
  • TABLE 113.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
  • TABLE 114.CRISPR THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 115.CRISPR THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 116.CRISPR THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 117.CRISPR THERAPEUTICS: NET SALES,
  • TABLE 118.CRISPR THERAPEUTICS: KEY STRATERGIES
  • TABLE 119.EDITAS MEDICINE: COMPANY SNAPSHOT
  • TABLE 120.EDITAS MEDICINE: OPERATING SEGMENTS
  • TABLE 121.EDITAS MEDICINE: PRODUCT PORTFOLIO
  • TABLE 122.EDITAS MEDICINE: NET SALES,
  • TABLE 123.EDITAS MEDICINE: KEY STRATERGIES
  • TABLE 124.EMMAUS LIFE SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 125.EMMAUS LIFE SCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 126.EMMAUS LIFE SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 127.EMMAUS LIFE SCIENCES, INC.: NET SALES,
  • TABLE 128.EMMAUS LIFE SCIENCES, INC.: KEY STRATERGIES
  • TABLE 129.GLOBAL BLOOD THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 130.GLOBAL BLOOD THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 131.GLOBAL BLOOD THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 132.GLOBAL BLOOD THERAPEUTICS, INC.: NET SALES,
  • TABLE 133.GLOBAL BLOOD THERAPEUTICS, INC.: KEY STRATERGIES
  • TABLE 134.MEDUNIC USA INC.: COMPANY SNAPSHOT
  • TABLE 135.MEDUNIC USA INC.: OPERATING SEGMENTS
  • TABLE 136.MEDUNIC USA INC.: PRODUCT PORTFOLIO
  • TABLE 137.MEDUNIC USA INC.: NET SALES,
  • TABLE 138.MEDUNIC USA INC.: KEY STRATERGIES
  • TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 142.NOVARTIS AG: NET SALES,
  • TABLE 143.NOVARTIS AG: KEY STRATERGIES
  • TABLE 144.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 145.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 146.NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 147.NOVO NORDISK: NET SALES,
  • TABLE 148.NOVO NORDISK: KEY STRATERGIES
  • TABLE 149.VIFOR PHARMA: COMPANY SNAPSHOT
  • TABLE 150.VIFOR PHARMA: OPERATING SEGMENTS
  • TABLE 151.VIFOR PHARMA: PRODUCT PORTFOLIO
  • TABLE 152.VIFOR PHARMA: NET SALES,
  • TABLE 153.VIFOR PHARMA: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.SICKLE CELL DISEASE TREATMENT MARKET SEGMENTATION
  • FIGURE 2.SICKLE CELL DISEASE TREATMENT MARKET,2021-2031
  • FIGURE 3.SICKLE CELL DISEASE TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.SICKLE CELL DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.SICKLE CELL DISEASE TREATMENT MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OXYBRYTA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ADAKVEO SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.SICKLE CELL DISEASE TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SICKLE CELL ANEMIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HBSC SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.SICKLE CELL DISEASE TREATMENT MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ORAL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF PARENTERAL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 26.SICKLE CELL DISEASE TREATMENT MARKET BY REGION,2021
  • FIGURE 27.U.S. SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.UK SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.CHINA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.INDIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.AGIOS PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 53.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
  • FIGURE 54.CRISPR THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 55.EDITAS MEDICINE.: NET SALES ,($MILLION)
  • FIGURE 56.EMMAUS LIFE SCIENCES, INC..: NET SALES ,($MILLION)
  • FIGURE 57.GLOBAL BLOOD THERAPEUTICS, INC..: NET SALES ,($MILLION)
  • FIGURE 58.MEDUNIC USA INC..: NET SALES ,($MILLION)
  • FIGURE 59.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 60.NOVO NORDISK.: NET SALES ,($MILLION)
  • FIGURE 61.VIFOR PHARMA.: NET SALES ,($MILLION)